Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/64011
Full metadata record
???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
---|---|---|
dc.contributor.advisor | 丁詩同(Shih-Torng Ding) | |
dc.contributor.author | Yu-Hsin Chien | en |
dc.contributor.author | 簡幼欣 | zh_TW |
dc.date.accessioned | 2021-06-16T17:26:25Z | - |
dc.date.available | 2015-08-19 | |
dc.date.copyright | 2012-08-19 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-08-15 | |
dc.identifier.citation | Alvarez, R. H., V. Valero and G. N. Hortobagyi. 2010. Emerging Targeted Therapies for Breast Cancer. J. Clin. Oncol. 28(20): 3366-3379.
Arellano-Garcia, M. E., R. Li, X. Liu, Y. Xie, X. Yan, J. A. Loo and S. Hu. 2010. Identification of Tetranectin as a Potential Biomarker for Metastatic Oral Cancer. Int. J. Mol. Sci. 11: 3106-3121. Bacac, M. and I. Stamenkovic. 2007. Metastatic cancer cell. Annu. Rev. Pathol. Mech. Dis. 3: 221-247. Begum, F. D, E. Høgdall, I. J. Christensen, L. Christensen, S. K. Kjaer, J. Blaakaer, A. L. Petri and C. Høgdall. 2010. Serum tetranectin as a preoperative indicator for postoperative complications in Danish ovarian cancer patients. Gynecol. Oncol. 117:446-450. Begum, F. D, E. Hogdall, I. J. Christensen, S. K. Kjaer, J. Blaakaer, L. Christensen and C. Hogdall. 2010. Serum tetranectin is a significant prognostic marker in ovarian cancer patients. Acta Obstet Gyn Scan. 89: 190-198 Berglund, L and T. E., Petersen. 1992. The gene structure of tetranectin, a plasminogen binding protein. FEBS. 309(1): 15-19. Brunner, A., C. Ensinger, M. Christiansen, S. Heiss, I. Verdorfer, G. Mikuz and A. Tzankov. 2007. Expression and prognostic significance of Tetranectin in invasive and non-invasive bladder cancer. Virchows Arch. 450: 659-664. Buzdar, AU, N. K. Ibrahim, D. Francis, D. J. Booser, E. S. Thomas, R. L. Theriault, L. Pusztai, M. C. Green, B. K. Arun, S. H. Giordano, M. Cristofanilli, D. K. Frye, T. L. Smith, K. K. Hunt, S. E. Singletary, A. A. Sahin, M. S. Ewer, T. A. Buchholz, D.Berry, and G. N. Hortobagyi. 2005. Significantly higher pathologic complete remission rate after neoadjuvant therapy with Trastuzumab, Paclitaxel, and Epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2–positive operable breast cancer. J Clin Oncol 23(16): 3676-2685. Christensen, I., N. Johansen, B. A. Jensen and I. Clemmensen. 1987. Immunohistochemical localization of a novel, human plasma protein, tetranectin, in human endocrine tissues. Histochemistry 87: 195-199. Christensen, L and I. Clemmensen. 1990. Differences in tetranectin immunoreactivity between benign and malignant breast tissue. Histochemistry 95(5): 427-33. Clemmensen, I. 1989. Calcium-dependent binding of tetranectin to fibrin. Thromb. Res. 55: 233-238. Clemmensen, I., L. C. Petersen and C. Kluft. 1986. Purification and haracterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin. Eur. J. Biochem. 156: 327-333. De Vries TJ, De Wit PE, Clemmensen I, Verspaget HW, Weidle UH, Bröcker EB, Ruiter DJ, Van Muijen GN. 1996. Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions. J. Pathol. 79(3): 260-265. Durkin, M. E., S. L. Naylor, R. Albrechtsen, et al 1997. Assignment of the gene for human tetranectin (TNA) to chromosome 3p22Rp21.3 by somatic cell hybrid mapping. Cytogenet Cell Genet. 76: 39-40. Fuhlendorff, J., I. Clemmensen and S. Manusson. 1987. Primary structure of tetranectin, a plasminogen kringle 4 binding plasma protein: homology with asialoglycoprotein receptors and cartilage proteoglycan core protein. Biochemistry 26(21): 6757-6764. Graversen, J. H., R. H. Lorentsen, C. Jacobsen, S. K. Moestrup, B. W. Sigurskjold, H. C. Thøgersen, and M. Etzerodt. 1998. The plasminogen binding site of the c-type lectin tetranectin is located in the carbohydrate recognition domain, and binding is sensitive to both calcium and lysine. J. Biochem. 273 (44): 29241–29246. Hanahan, D. and R. Weinberg . 2000. The hallmarks of cancer. Cell 100: 57–70. Hittel, D. S., W. E. Kraus and E. P. Hoffman. 2003. Skeletal muscle dictates the fibrinolytic state after exercise training in overweight men with characteristics of metabolic syndrome. J. Physiol. 548(2): 401–410. Hogdall C., IB J. Christensen, R. W. Stephens, S. Sorensen, B. Norgaard-Pedersen and H. J. Nielsen. 2002. Serum tetranectin is an independent prognostic marker in colorectal cancer and weakly correlated with plasma suPAR, plasma PAI-1 and serum CEA. APMIS. 110: 630-638. Holtet, T. L., J. H. Graversen, I. Clemmensen, H. C. Thogersen and M. Etzerodt. 1997. Tetranectin, a trimeric plasminogen-binding C-type lectin. Protein Sci. 6: 1511-1515. Kamper, E., A. D. Papaphilis, M. K. Angelopoulou, L. T. Kopeikina, M. P. Siakantatris, G. A. Pangalis and J. C. Stavrids. 1999. Serum levels of tetranectin, intercellulae adhesion molecule-1 and interleukin-10 in B-Chronic lymphocytic leukemia. Clin. Biochem. 32(8): 639-645. Kluft, C., A. F., Jie, P. Los, E. de Wit and L. Havekes. 1989. Functional analogy between lipoprotein (a) and plasminogen in the binding to kringle 4 binding protein, tetranectin. Biochem. Biophys. Res. Commun. 161, 427-433. Kousuke, I, M. E. Durkin, L. Johnsen,E. Hunziker, K. Damgaard-Pedersen, H. Zhang, E. Engvall, R. Albrechtsen and U. M. Wewer1. 2001. Mice with a Targeted Deletion of the Tetranectin Gene Exhibit a Spinal Deformity. Mol. Cell. Biol. vol. 21(22): 7817-7825. Kousuke, I., N. Hatakeyama, T. Kojima, M. Murata, T. Matsumura, U. M. Wewer, T. Wada, N. Sawada and T. Yamashita. 2008. Impaired cutaneous wound healing in mice lacking tetranectin. Wound Repair Regen. 17: 108–112. Kuang, E. E. and R. Albrechtsen. 1998. Tetranectin is a novel marker for myogenesis during embryonic development, muscle regeneration, and muscle cell differentiation in vitro. Dev. Biol. 200: 247–259. Mogues T, Etzerodt M, Hall C, Engelich G, Graversen JH, Hartshorn KL. 2004. Tetranectin Binds to the Kringle 1-4 Form of Angiostatin and Modifies Its Functional Activity. J Biomed Biotechnol. 2004(2):73-78. Nielsen, B. B., J. S. Kastrup, H. Rasmussen, T. L. Holtet, J. H. Grav-ersen, M. Etzerodt, H. C. Thøgersen, and I. K. Larsen. 1997. Crystal structure of tetranectin, a trimeric plasminogen-binding protein with an a-helicalcoiledcoil. FEBS. 412: 388-396. Obrist, P., G Spizzo, C Ensinger, D Fong, T Brunhuber, G Schafer, M Varga, R Margreiter,A Amberger, G Gastl, M Christiansen. 2004. Aberrant tetranectin expression in human breast carcinomas as a predictor of survival. J. Clin Pathol. 57: 417-421. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP. 1999. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem. 7 (19):13066-13076. Sumiyoshi, K., K, Serizawa, T Urano, Y Takada, A Takada and S Baba. 1992. Plasminogen activator system in human breast cancer. Int. J. Cancer. 50:345-348. Westergaard, U. B., M. H. Andersen. C. W. Heegaard, S. N. Fedosov and T. E. Petersen. 2003. Tetranectin binds hepatocyte growth factor and tissue-type plasminogen activator. Eur. J. Biochem. 270: 1850-1854. Wewer, U. M., K. Iba, M. E. Durkin, F. C. Nielsen, F. Loechel, B. J.Gilpin, W. Kuang, E. Engvall and R. Albrechtsen. 1998. Tetranectin is a novel marker for myogenesis during embryonic development, muscle regeneration, and muscle cell differentiation in vitro. Dev. Biol. 200: 247–259. Wewer, U. M., K. Ibaraki, P. Schjørring, M. E. Durkin, M. F. Young and R. Albrechtsen. 1994. A potential role for tetranectin in mineralization during osteogenesis. J. Cell Biol. 127: 1767–1775. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/64011 | - |
dc.description.abstract | 乳癌是全球女性中最常見的癌症種類。尤其近年來由於女性月經初潮提早發生,導致乳癌發病年齡層有年輕化的傾向。此情況不僅在全球,在台灣也有相同的趨勢。因此,乳癌對於婦女健康是ㄧ重大問題而不容忽視。先前研究指出tetranectin (TN)可做為多項人類腫瘤之可靠生物標記,包括乳癌、卵巢癌、口腔癌和膀胱癌…等等。正常情況下,TN在人體血漿中維持一定之濃度。相較於健康者,研究發現罹癌者會出現TN顯著降低的情況,並且又與乳癌患者的病癒存活 (disease-free survivl)及整體存活 (overall survival)有顯著的相關性。低濃度TN則為乳癌轉移的高危險指標,並且在乳腺腫瘤區域胞外基質 (extracellular matrix)表現出更強烈的免疫反應。因此,本研究的目的乃在釐清TN於乳癌細胞株中的功能及其分子機制。
首先,我們於非腫瘤乳腺上皮細胞株MCF10A,三類乳腺癌細胞株 (MCF7、MDA-MB-231和SKBR3)與乳腺導管上皮細胞株BT474中,分別比較TN的蛋白質表現量。結果顯示,在上述之乳癌細胞株中,除MCF10A外,TN皆可在全細胞萃取質 (whole-cell lysates) 和細胞培養液 (conditioned medium)中被偵測到。此外,我們也構築Myc-His-標記 (tagged) TN、TN-綠螢光 (GFP)融合蛋白或去訊息片段 (signal peptide-deficient-)TN-綠螢光之質體DNA載體,再分別將其轉染至MCF7細胞以分析受TN所影響的細胞功能。結果證實於軟洋菜膠 (soft agar)中培養時,全長(full-length) TN皆可增加細胞的非貼附性生長 (anchorage independent growth),而不影響細胞存活率 (cell viability)。更有甚者,我們亦發現全段TN可顯著增進細胞的活動力 (cell motility);然而,卻不見於去訊息片段者;此顯示TN於細胞運動中扮演胞外刺激因子的角色。 綜合上述,本研究中發現,TN表現於乳癌細胞株而非正常乳腺上皮細胞中。然而在MCF7細胞株中過量表現TN,可增加細胞活動及非貼附性生長,卻不影響細胞的存活。這些功能上的影響支持TN能在乳腺癌腫瘤的發展中發揮重要作用之假說。至於TN參與腫瘤發展的分子機制仍有待澄清。 | zh_TW |
dc.description.abstract | Breast cancer is the most common type of cancer in the females worldwide. In recent years, early onset of menarche leads to an increase in the incidence of such cancer in younger woman populations of the world, including Taiwan. Therefore, breast cancer has become a serious health issue for women. Tetranectin (TN) has been found to be a reliable biomarker in certain human carcinoma, including breast cancer, ovary cancer, oral cancer and bladder cancer. Consistently, TN is related to the disease-free and overall survival of breast cancer. Low TN concentrations in human plasma were reported as a high-risk factor for breast cancer metastasis. Interestingly, there has also been shown a strong immunoreactivity in the extracellular matrix associated with breast tumor malignancy. Thus, the purpose of this study was to elucidate the cellular functions of TN and the underlying mechanisms in breast cancer cell line.
First, we compared the protein expression of TN in non-tumorigenic epithelial cell line MCF10A, three breast adenocarcinoma cell lines (MCF7, MDA-MB-231 and SKBR3), and the breast ductal carcinoma cell line BT474, and found that TN was detected in both the whole-cell lysates and conditioned media of all breast cancer cell lines, except MCF10A. We then generated the expression constructs of Myc-His-tagged or GFP-fused full-length and signal peptide-deficient TN and transfected each into MCF7 cells to analyze TN-modulated cellular functions. Our results indicate that TN overexpression increased anchorage independent growth in a soft agar assay without affecting cell viability. Interestingly, we also found that TN prominently promoted cell motility, which was not seen for the signal peptide-deficient TN, indicating a role of TN in modulating cell movement is be an extracellular stimulator. In conclusion, we demonstrated in this study that TN is normally up-regulated in breast cancer cell lines, but not in normal breast epithelial cells. When overexpressed, TN increases cell motility and anchorage independent growth in MCF7cell, without affecting cell survival. These support the hypothesis that TN plays an important role in tumor development of breast cancer. Nevertheless, the molecular mechanisms underlying TN-mediated tumor progression remain to be elucidated. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T17:26:25Z (GMT). No. of bitstreams: 1 ntu-101-R99626006-1.pdf: 1263444 bytes, checksum: 0749b38d5ebe4be1bbcdc80f11447bbd (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | CONTENTS
中文摘要 V Abstract VI Introduction 1 Cancer 1 Breast cancer 2 Tetranectin 5 Structure 6 Function 7 Role in cancer 9 The aim of study 11 Materials and Methods 12 Reagents 12 Constructs and mutagenesis 13 Cell culture 14 Cell transfection 14 Western blotting analysis 16 Pooled stable clones of TN-expressed Cells 17 Cell motility assay 17 Tumorigenesis assay 18 Cell viability 19 Results 20 Tetranectin protein is detected in breast cancer cell lines 20 Cell viability is not affected by myc-His-TN expression 21 TN is involved in anchorage independent growth 22 Generation of signal peptide-deficient TN mutant 23 TN could not affect cell viability in GFP system 23 Full length TN affects anchorage independent growth 24 Ectopic expression of TN promotes cell motility 25 Discussion 27 Reference 45 Figures and figure legends Figure 1. Detection of tetranectin protein in human breast cancer cell lines. 31 Figure 2. Expression of TN in human embryonic kidney (HEK) 293T and breast cancer cell line MCF-7. 33 Figure 3. Effects of TN-overexpressionon cell viability of MCF-7 cells. 34 Figure 4. Effects of myc-His-TN overexpression on anchorage independent grwth of MCF-7 cells. 36 Figure 5. Expression of TN and TN mutant in in human breast cancer cell line MCF-7. 39 Figure 6. Effects of TN-GFP fusions on cell viability of MCF-7 cells. 40 Figure 7. Effects of TN-GFP overexpression on anchorage independent growth of MCF-7 cells. 42 Figure 8. Effects of TN-GFP fusions on cell motility of MCF-7 cells. 43 Figure 9. Modulation of signaling events by TN in MCF-7 cells. 44 | |
dc.language.iso | en | |
dc.title | Tetranectin在乳癌細胞株MCF-7中所扮演的角色 | zh_TW |
dc.title | The role of tetranectin in human breast MCF-7cancer cell line | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 沈湯龍(Tang-Long Shen) | |
dc.contributor.oralexamcommittee | 李心予(Hsin-Yu Lee),黃敏銓(Min-Chuan Huang) | |
dc.subject.keyword | tetranectin,乳癌,非貼附性生長,細胞活動力,細胞存活率, | zh_TW |
dc.subject.keyword | tetranectin,breast cancer,anchorage independent growth,cell viability,cell motility, | en |
dc.relation.page | 50 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-08-16 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 動物科學技術學研究所 | zh_TW |
Appears in Collections: | 動物科學技術學系 |
Files in This Item:
File | Size | Format | |
---|---|---|---|
ntu-101-1.pdf Restricted Access | 1.23 MB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.